Friday, November 20, 2026

Designing a Credible Nutraceutical Study: Endpoints, Placebo and Sample Size

Last Friday I wrote about why nutraceutical companies need clinical evidence. Today: how to design a study that people will actually believe.

A study's credibility is decided at the design stage. No amount of good monitoring can rescue a poorly designed trial.

1. Start with the claim

Write down the exact claim you want to make, for example "supports healthy joint mobility in adults". Every design choice should serve that claim. Studies designed to "see what happens" rarely support any claim well.

2. Choose the right population

Enrol people who match the intended consumers – for instance, healthy adults with mild symptoms rather than patients with diagnosed disease, since nutraceuticals cannot make disease claims. Clear inclusion and exclusion criteria reduce variability.

3. Pick meaningful, measurable endpoints

  • Use validated tools where possible: standard questionnaires, recognised biomarkers or objective measurements.
  • Define one primary endpoint that directly reflects the claim.
  • Keep secondary endpoints limited and relevant.
  • Avoid vague endpoints such as "overall wellbeing" without a validated scale.

4. Use a proper comparator

A randomised, double-blind, placebo-controlled design remains the most persuasive. Nutraceutical effects are often modest, and placebo effects can be large, especially for subjective outcomes. Without a placebo, it is almost impossible to show that your product, not expectation, caused the change.

Matching placebo appearance, taste and smell matters, particularly for powders, beverages and herbal extracts.

5. Justify the sample size

Too small and the study cannot detect a real effect; too large and you waste resources. Work with a statistician to calculate the sample size from the expected effect size, variability and allowance for drop-outs. Document the calculation in the protocol.

6. Choose a realistic duration

The study must be long enough for the effect to appear and, ideally, to show it is maintained. Duration should be based on the biology of the ingredient and previous evidence.

7. Plan for compliance and diet

Nutraceutical outcomes can be influenced by diet, exercise and other supplements. Record and, where needed, control these. Track product compliance with returns or diaries.

8. Register and pre-specify

Register on CTRI before enrolment and pre-specify endpoints and analysis in the protocol. This prevents any suspicion of selective reporting.

9. Run it to GCP standards

Ethics approval, proper consent, monitoring and documentation turn a promising design into trustworthy evidence.

A quick design checklist

  • Claim clearly defined?
  • Population matches the target consumer?
  • Validated primary endpoint?
  • Randomised and placebo-controlled?
  • Sample size justified?
  • Registered on CTRI?
  • Independent monitoring planned?

Planning a nutraceutical study? I can review your protocol and provide independent monitoring. Write to me at anup.cra@gmail.com.

– Anup Kumar, Independent Clinical Research Auditor & Consultant, New Delhi

Thursday, November 19, 2026

SAE Reporting in India: Getting Safety Timelines Right

Few things worry regulators more than late or incomplete safety reporting. In India, the New Drugs and Clinical Trials Rules, 2019 set clear timelines for serious adverse events (SAEs) – and missing them is one of the most frequent findings in audits and inspections.

This post is general guidance; always confirm against the current Rules and CDSCO guidance.

What counts as an SAE?

An adverse event is serious if it results in death, is life-threatening, requires or prolongs hospitalisation, causes persistent or significant disability, or results in a congenital anomaly – or is otherwise considered medically important.

The key timelines

  • Within 24 hours of becoming aware: the investigator reports the SAE to the Central Licensing Authority, the sponsor and the Ethics Committee.
  • Within 14 days: a detailed report with analysis, including causality, is submitted.

The Ethics Committee and the licensing authority then review the event, including whether it is related to the trial and whether compensation applies.

Where things go wrong

  1. Delayed awareness. Participants are admitted to another hospital and the site learns about it days later.
  2. Weekend and holiday gaps. The PI is unavailable and no backup is named.
  3. Incomplete initial reports. The 24-hour report is delayed while waiting for full information. Report what you know – follow-up can come later.
  4. Causality not documented. The investigator's assessment of relatedness is missing or unsigned.
  5. Different clocks. Global sponsor processes based on other countries' timelines are not adjusted for India.
  6. Poor reconciliation. SAEs in the safety database don't match those in the clinical database.

Practical steps for sites

  • Give every participant a card with 24-hour contact numbers and instructions to inform the site of any hospital visit.
  • Name a backup investigator for reporting when the PI is away.
  • Keep reporting forms and contact details ready in one place.
  • Record the date and time of awareness clearly – the clock starts there.
  • Track every SAE through to resolution in an SAE log.

Practical steps for sponsors

  • Make sure your safety management plan reflects Indian timelines.
  • Train sites at initiation and re-train after any late report.
  • Monitor SAE reporting timeliness as a key risk indicator.
  • Perform regular reconciliation between the safety and clinical databases.
  • Audit safety processes at high-risk sites.

Why it matters

Timely SAE reporting protects participants first and foremost. It also determines whether compensation decisions can be made fairly and on time – an area that regulators and the public watch closely in India.

Want an independent review of safety reporting at your sites? Write to me at anup.cra@gmail.com.

– Anup Kumar, Independent Clinical Research Auditor & Consultant, New Delhi

Wednesday, November 18, 2026

Trial Master File Health Check: Is Your TMF Inspection-Ready?

Inspectors often say: "If it isn't documented, it didn't happen." The Trial Master File (TMF) is where that documentation lives. It should allow anyone – an auditor, an inspector, a future partner – to reconstruct how your trial was conducted and judge whether it was done correctly.

Under ICH E6(R3), the emphasis is on essential records that tell the trial's story, not on ticking off a fixed list of documents. Yet in many audits I find TMFs that are incomplete, disorganised or filled in only at the end of the study.

Common TMF problems

  • Documents filed months late, or only before close-out
  • Missing approvals for protocol amendments or consent versions
  • Gaps in correspondence with Ethics Committees and CDSCO
  • Monitoring visit reports without follow-up letters or action closure
  • Unsigned or undated documents
  • Inconsistencies between the sponsor TMF and the investigator site file
  • eTMF systems with poor indexing, so documents cannot be found

A quick TMF health check

Pick one site and ask these questions:

  1. Completeness: Is every expected document present for the current stage of the study?
  2. Timeliness: Were documents filed within your agreed timeline (for example, within 30 days)?
  3. Quality: Are documents legible, signed, dated and final versions?
  4. Consistency: Do dates and versions match across the TMF, site file and EC approvals?
  5. Story: Could an outsider follow the study timeline – approvals, start-up, monitoring, issues and resolutions?
  6. Retrievability: Can you find any requested document within minutes?

If you struggle with any of these for one site, it is likely the problem exists across the study.

Building a healthy TMF

  • Use a reference model. An industry-standard TMF index gives structure and avoids gaps.
  • File as you go. Make TMF filing part of each process, not a separate end-of-study task.
  • Run periodic QC. A quarterly completeness and quality review catches problems early.
  • Track metrics: completeness percentage, filing timeliness and QC error rate.
  • Assign ownership. Every document type should have a responsible person.
  • Reconcile with sites. Compare the site file with the TMF at key milestones.

Why it matters commercially

A strong TMF is not only for inspectors. If you plan to license your product, seek investment or submit data to foreign regulators, buyers and reviewers will examine your TMF. Gaps raise doubts about the entire dataset.

Independent TMF audits

An independent TMF audit before database lock or submission gives you a clear list of gaps while there is still time to fix them.

Need a TMF audit or inspection-readiness review? Write to me at anup.cra@gmail.com.

– Anup Kumar, Independent Clinical Research Auditor & Consultant, New Delhi

Tuesday, November 17, 2026

What Actually Happens During a GCP Audit? A Step-by-Step Walkthrough

The word "audit" makes many site teams nervous. In reality, a well-run GCP audit is a structured, respectful process designed to help – to find problems while they can still be fixed. Here is what actually happens.

Step 1: Planning

The audit begins long before the visit. The sponsor and auditor agree:

  • Scope – which site, vendor or process will be audited
  • Objectives – routine, for-cause, pre-inspection or close-out
  • Criteria – protocol, ICH GCP, NDCT Rules, sponsor and site SOPs

The auditor reviews the protocol, monitoring reports, deviation logs and data listings to identify areas of risk. This is where an experienced auditor adds the most value: knowing where to look.

Step 2: Audit plan and notification

The site or vendor receives an audit plan with dates, agenda, documents needed and the people the auditor wishes to meet. Good preparation by the site makes the visit efficient.

Step 3: Opening meeting

A short meeting with the PI and team to introduce the auditor, confirm the scope and agenda, and answer questions. This sets a professional, collaborative tone.

Step 4: The audit itself

Typically over one to three days, the auditor:

  • Reviews documents: investigator site file, consent forms, delegation logs, training records, EC correspondence
  • Verifies data: compares CRF data with source documents for a sample of participants
  • Checks processes: IP storage and accountability, SAE reporting, sample handling
  • Interviews staff: asks how tasks are done in practice, not just what the SOP says
  • Tours facilities: storage areas, equipment, archives

Step 5: Closing meeting

The auditor shares preliminary observations verbally. There should be no surprises in the final report. This is also the site's chance to clarify misunderstandings or provide missing documents.

Step 6: Audit report

Within an agreed time, the auditor issues a written report. Findings are usually graded:

  • Critical – affects participant safety, rights or data reliability; needs immediate action
  • Major – significant non-compliance that could affect data or safety
  • Minor – deviations from good practice that should be corrected

Each finding states the requirement, what was observed and the evidence.

Step 7: CAPA and follow-up

The site or vendor responds with corrective and preventive actions, including root cause, actions, owners and timelines. The auditor or sponsor reviews the responses and follows up until findings are closed.

What makes an audit valuable

  • Independence – findings are reported without bias
  • Risk focus – time spent where it matters most
  • Clear evidence – every finding is traceable
  • Practical recommendations – fixes that work for busy Indian sites

An audit is not a fault-finding exercise. It is the best preparation for a regulatory inspection you will ever get.

Planning an audit of a site, CRO or study in India? Write to me at anup.cra@gmail.com.

– Anup Kumar, Independent Clinical Research Auditor & Consultant, New Delhi